Vial

DECEMBER 11, 2023

Hepatitis C virus (HCV) infection is a global health problem with complications that place a significant economic burden on national health systems. The Food and Drug Administration (FDA) approved and recommended dozens of small-molecule drugs. On top of this, treated individuals are susceptible to reinfection.

Clinical Research 52

Clinical Research Therapies Research Vaccine 52

Drug Target Review

JULY 11, 2023

In simple terms, our immune system is divided into innate and adaptive responses – the innate being the first line of defence, and the adaptive responds to specific challenges by modifying the body’s immune response in a tailored fashion. B-cell white blood cell, type of lymphocyte produce antibody molecules.

Disease 75

Disease RNA Small Molecule Clinical Development 75

The Pharma Data

OCTOBER 14, 2020

(Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the first participant was enrolled in the observational PRECISION study (TNX-C002), to examine the immune responses to COVID-19 in healthy volunteers who have recovered from COVID-19 or were asymptomatic. About TNX-1800.

Vaccine 40

Vaccine Pharmaceuticals Small Molecule Virus 40

The Pharma Data

DECEMBER 15, 2020

Small Molecule Inhibitors. NMD670 is a first-in-class small molecule inhibitor of the muscle specific chloride ion channel, the ClC-1 ion channel. Oral, Small Molecules. CUE-300 Series Immuno-STATs may offer autoimmune patients therapeutic benefits without compromising their immune systems.

Disease 52

Disease Clinical Trials Small Molecule Trials 52

Codon

DECEMBER 12, 2024

A mirrored organism would use right-handed molecules everywhere a naturally-occurring organism uses left-handed ones, and vice versa. It would also be undetectable by key parts of the human immune system. The rabies virus infects most mammals and typically spreads through saliva (delivered via animal bites).

RNA 102

RNA DNA Vaccine Virus 102

The Pharma Data

DECEMBER 20, 2020

It is an optimized, non-chemically modified mRNA that codes for the prefusion stabilized full-length spike protein of the SARS-CoV-2 virus. Pfizer and BioNTech announced additional data on neutralizing antibody and T-cell responses from their Phase I/II trial of their COVID-19 vaccine conducted in Germany.

Vaccine 52

Vaccine Trials Therapies Small Molecule 52

The Pharma Data

SEPTEMBER 9, 2020

(NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced preliminary preclinical data in mouse and non-human primate models from their BNT162b2 mRNA-based vaccine program against SARS-CoV-2, the virus that causes COVID-19 disease. producing CD8+ T cell responses, which is thought to promote an anti-viral effect.

Vaccine 52

Vaccine Clinical Trials RNA Trials 52

The Pharma Data

AUGUST 20, 2020

T cell immune responses elicited by BNT162b2 are being evaluated in the German study and the companies expect to submit the data for peer review and potential publication. trial and we look forward to sharing T cell immune response data from the German trial in the near future.”. This press release features multimedia.

Vaccine 52

Vaccine Clinical Trials Trials Immune Response 52

Codon

APRIL 30, 2023

In one experiment, the microneedle patches were used to deliver a SARS-CoV-2 vaccine into mice, producing immune responses similar to a traditional injection. Printed vaccines caused mice to have a faster immune response. It’s an easier way to get CRISPR into cells! But the printed vaccines are very good!

Vaccine 52

Vaccine DNA Engineering RNA 52

Codon

APRIL 30, 2023

In one experiment, the microneedle patches were used to deliver a SARS-CoV-2 vaccine into mice, producing immune responses similar to a traditional injection. Printed vaccines caused mice to have a faster immune response. It’s an easier way to get CRISPR into cells! But the printed vaccines are very good!

Vaccine 52

Vaccine DNA Engineering RNA 52

The Pharma Data

SEPTEMBER 15, 2020

Based on the acceptable safety profile and the favorable immune response data, including the 4th dose response data, Pfizer received Breakthrough Therapy Designation. An update on Pfizer’s potential first-in-class maternal vaccine candidate for the prevention of respiratory syncytial virus (RSVpreF). for RSV A and 18.0

Vaccine 52

Vaccine Therapies Trials Clinical Trials 52

The Pharma Data

APRIL 27, 2021

MRT5500 (SP0254), an mRNA vaccine candidate against SARS-CoV-2, entered Phase 1/2 to assess safety, immune response and reactogenicity. SAR441566 , a first, next generation, oral small molecule TNF inhibitor that in contrast to anti-TNF biologics blocks specifically the TNFR1 pathway, started Phase I in inflammatory conditions.

Vaccine 52

Vaccine Production FDA Disease 52

The Pharma Data

APRIL 15, 2022

These data reinforce the potential function of a third dose of the vaccine in maintaining high levels of protection against the virus in this age group. The neutralizing GMT against the wild-type virus was 2153 (after three doses), compared to 335 after two doses.

Immune Response 52

Immune Response Vaccine Clinical Trials Virus 52

The Pharma Data

MARCH 11, 2021

This clearly demonstrates the power of the COVID-19 vaccine to fight this virus and encourages us to continue even more intensively with our vaccination campaign. Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to the Pfizer-BioNTech COVID-19 Vaccine.

Vaccine 52

Vaccine Clinical Trials Hospitals Licensing 52

The Pharma Data

MAY 7, 2021

Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to the Pfizer-BioNTech COVID-19 Vaccine. The Pfizer-BioNTech COVID-19 Vaccine may not protect all vaccine recipients.

Licensing 52

Licensing Licensing Vaccine FDA Approval 52

The Pharma Data

JULY 21, 2021

Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to the Pfizer-BioNTech COVID-19 Vaccine. Procedures should be in place to avoid injury from fainting. The Pfizer-BioNTech COVID-19 Vaccine may not protect all vaccine recipients.

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

The Pharma Data

MAY 6, 2021

Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to the Pfizer-BioNTech COVID-19 Vaccine. The Pfizer-BioNTech COVID-19 Vaccine may not protect all vaccine recipients.

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

The Pharma Data

DECEMBER 10, 2020

The Phase 3 trial is designed as a 1:1 vaccine candidate to placebo, randomized, observer-blinded study to obtain safety, immune response, and efficacy data needed for regulatory review. The study also will explore prevention of infection by SARS-CoV-2, the virus that causes COVID-19.

Vaccine 52

Vaccine Trials Clinical Trials Therapies 52

The Pharma Data

DECEMBER 27, 2020

It is a selective modulator of neuropilin-2 that downregulates the innate and adaptive immune response in inflammatory diseases. Transgene and BioInvent International received regulatory approval in Belgium for a Phase I/IIa trial of oncolytic Vaccinia virus BT-001. platforms and the human GM-CSF cytokine.

Trials 52

Trials Clinical Trials Therapies RNA 52

The Pharma Data

SEPTEMBER 8, 2020

Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules.

Science 52

Science Vaccine Clinical Trials Pharmaceutical Companies 52

The Pharma Data

SEPTEMBER 8, 2020

Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules.

Science 52

Science Vaccine Clinical Trials Pharmaceutical Companies 52

The Pharma Data

DECEMBER 11, 2020

The Phase 3 trial is designed as a 1:1 vaccine candidate to placebo, randomized, observer-blinded study to obtain safety, immune response, and efficacy data needed for regulatory review. The study also will explore prevention of infection by SARS-CoV-2, the virus that causes COVID-19.

Vaccine 52

Vaccine Clinical Trials Trials Licensing 52

The Pharma Data

SEPTEMBER 9, 2020

During preclinical and clinical studies, BNT162b1 and BNT162b2 emerged as strong candidates based on assessments of safety and immune response. BNT162b2 encodes an optimized SARS-CoV-2 full-length spike glycoprotein (S), which is the target of virus neutralizing antibodies. and Germany as well as animal immunogenicity studies.

Vaccine 52

Vaccine Clinical Trials Trials Government 52

Codon

MARCH 26, 2023

Link A DNA tumor virus globally reprograms host 3D genome architecture to achieve immortal growth. Link *Design of Four Small-Molecule-Inducible Systems in the Yeast Chromosome, Applied to Optimize Terpene Biosynthesis. Link A generalizable nanopore sensor for highly specific protein detection at single-molecule precision.

DNA 52

DNA Engineering RNA Science 52

The Pharma Data

JUNE 24, 2021

Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to the Pfizer?BioNTech Procedures should be in place to avoid injury from fainting. BioNTech COVID-19 Vaccine. The Pfizer?BioNTech BioNTech COVID-19 Vaccine may not protect all vaccine recipients.

Government 52

Government Vaccine Clinical Trials Licensing 52

Codon

APRIL 16, 2023

Skin microbes can trigger strong immune responses. These microbes were engineered to express tumor antigens that could “elicit T cells that were licensed by the commensal immune program but specific for a tumor,” including both CD4+ and CD8+ T cells, according to the study. Nature Communications. Science Advances.

Engineering 52

Engineering DNA RNA Science 52